Researchers develop lung cancer screening model for smokers, former smokers
نویسندگان
چکیده
منابع مشابه
Lung cancer chemoprevention with celecoxib in former smokers.
Ample studies suggest that the cyclooxygenase-2 (COX-2)/prostaglandin E(2) (PGE(2)) pathway plays a pivotal role in carcinogenesis and that COX-2 inhibition may help prevent lung cancer. Therefore, we conducted a randomized, double-blind, placebo-controlled trial of the COX-2-selective inhibitor celecoxib (400 mg bid for 6 months) in former-smokers (age ≥ 45, ≥ 30 pack-years of smoking, ≥ 1 yea...
متن کاملBenchmarking lung cancer mortality rates in current and former smokers.
STUDY OBJECTIVES To develop and validate a model for estimating the risk of lung cancer death in current and former smokers. The model is intended for use in analyzing a population of subjects who are undergoing lung cancer screening or receiving lung cancer chemoprevention, to determine whether the intervention has altered lung cancer mortality. DESIGN/SETTING/PATIENTS Model derivation was b...
متن کاملA qualitative analysis of smokers’ perceptions about lung cancer screening
BACKGROUND In 2013, the US Preventive Services Task Force (USPSTF) began recommending lung cancer screening for high risk smokers aged 55-80 years using low-dose computed tomography (CT) scan. In light of these updated recommendations, there is a need to understand smokers' knowledge of and experiences with lung cancer screening in order to inform the design of patient education and tobacco ces...
متن کاملLung cancer in non-smokers
The decrease in lung cancer mortality in many Western societies is being attributed to a large extent to smoking prevention measures. However, lung cancer also occurs in nonsmokers, with an estimated frequency of 10–25%. The identification of oncogenic driver alterations which are successfully targetable, being more prevalent in lung cancer in non-smokers, has encouraged interest in these tumor...
متن کاملLung cancer in never-smokers.
The therapeutic landscape of lung cancer has evolved tremendously over the past 10 years with the discovery of oncogenic drivers constitutively activated by mutation, translocation or fusion. An activating EGFR mutation or ALK rearrangement is present in around 15% of Caucasian patients with non-small cell lung cancer (NSCLC), with targeted therapy constituting the basis of upfront treatment fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2016
ISSN: 0008-543X
DOI: 10.1002/cncr.30409